Hypertonic saline for cerebral edema and elevated intracranial pressure

Research output: Contribution to journalArticle

Abstract

The use of HS solutions has been shown to reduce ICP both in animal models and in human studies in a variety of underlying disorders, even in cases refractory to treatment with hyperventilation and mannitol. There are several possible mechanisms of action, and important complications such as central pontine myelinolysis and intracranial hemorrhage have not been reported in the human studies. Different types of HS solutions with different methods of infusion (bolus and continuous) have been used in the past, and so far there are not enough data to recommend one concentration over another. Many issues remain to be clarified, including the exact mechanism of action of HS, the best mode of administration and HS concentration to be given, and the relative efficacy of HS vis-á-vis available treatments, particularly mannitol.

Original languageEnglish (US)
JournalCleveland Clinic Journal of Medicine
Volume71
Issue numberSUPPL.1
DOIs
StatePublished - Dec 1 2003
Externally publishedYes

Fingerprint

Intracranial Hypertension
Brain Edema
Mannitol
Central Pontine Myelinolysis
Hyperventilation
Intracranial Hemorrhages
Animal Models

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hypertonic saline for cerebral edema and elevated intracranial pressure. / Suarez, Jose.

In: Cleveland Clinic Journal of Medicine, Vol. 71, No. SUPPL.1, 01.12.2003.

Research output: Contribution to journalArticle

@article{c87cc438b53f4670bc938d9a96f67a8e,
title = "Hypertonic saline for cerebral edema and elevated intracranial pressure",
abstract = "The use of HS solutions has been shown to reduce ICP both in animal models and in human studies in a variety of underlying disorders, even in cases refractory to treatment with hyperventilation and mannitol. There are several possible mechanisms of action, and important complications such as central pontine myelinolysis and intracranial hemorrhage have not been reported in the human studies. Different types of HS solutions with different methods of infusion (bolus and continuous) have been used in the past, and so far there are not enough data to recommend one concentration over another. Many issues remain to be clarified, including the exact mechanism of action of HS, the best mode of administration and HS concentration to be given, and the relative efficacy of HS vis-{\'a}-vis available treatments, particularly mannitol.",
author = "Jose Suarez",
year = "2003",
month = "12",
day = "1",
doi = "10.3949/ccjm.71.Suppl_1.S9",
language = "English (US)",
volume = "71",
journal = "Cleveland Clinic Journal of Medicine",
issn = "0891-1150",
publisher = "Cleveland Clinic Educational Foundation",
number = "SUPPL.1",

}

TY - JOUR

T1 - Hypertonic saline for cerebral edema and elevated intracranial pressure

AU - Suarez, Jose

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The use of HS solutions has been shown to reduce ICP both in animal models and in human studies in a variety of underlying disorders, even in cases refractory to treatment with hyperventilation and mannitol. There are several possible mechanisms of action, and important complications such as central pontine myelinolysis and intracranial hemorrhage have not been reported in the human studies. Different types of HS solutions with different methods of infusion (bolus and continuous) have been used in the past, and so far there are not enough data to recommend one concentration over another. Many issues remain to be clarified, including the exact mechanism of action of HS, the best mode of administration and HS concentration to be given, and the relative efficacy of HS vis-á-vis available treatments, particularly mannitol.

AB - The use of HS solutions has been shown to reduce ICP both in animal models and in human studies in a variety of underlying disorders, even in cases refractory to treatment with hyperventilation and mannitol. There are several possible mechanisms of action, and important complications such as central pontine myelinolysis and intracranial hemorrhage have not been reported in the human studies. Different types of HS solutions with different methods of infusion (bolus and continuous) have been used in the past, and so far there are not enough data to recommend one concentration over another. Many issues remain to be clarified, including the exact mechanism of action of HS, the best mode of administration and HS concentration to be given, and the relative efficacy of HS vis-á-vis available treatments, particularly mannitol.

UR - http://www.scopus.com/inward/record.url?scp=84884585159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884585159&partnerID=8YFLogxK

U2 - 10.3949/ccjm.71.Suppl_1.S9

DO - 10.3949/ccjm.71.Suppl_1.S9

M3 - Article

C2 - 14964472

AN - SCOPUS:84884585159

VL - 71

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

SN - 0891-1150

IS - SUPPL.1

ER -